Turning Point Therapeutics, Inc. - Common stock (NQ:TPTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Turning Point Therapeutics, Inc. - Common stock

< Previous 1 2 Next >

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

August 16, 2022

From Bristol Myers Squibb

Via Business Wire

Blue Chip Stocks In Focus: Bristol-Myers Squibb ↗

August 15, 2022

The company has grown earnings by more than 20% per year on average over the last five and ten years. This explosive growth has enabled the company to continue growing its dividend.

Via Talk Markets

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 27, 2022

Via Benzinga

Analyst Ratings for Turning Point ↗

June 06, 2022

Within the last quarter, Turning Point (NASDAQ:TPTX) has observed the following analyst ratings:

Via Benzinga

Turning Point Inks Licensing Pact For Gastrointestinal Cancers Candidate ↗

May 05, 2022

Via Benzinga

Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission ↗

July 27, 2022

Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter.

Via Benzinga

The 3 Best Market Sectors for the Second Half of 2022 ↗

July 27, 2022

Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into.

Via InvestorPlace

TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders

July 05, 2022

From Halper Sadeh LLP

Via Business Wire

TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX

July 05, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up ↗

June 25, 2022

Shockwave and UnitedHealth lead 5 stocks that are setting up or breaking out.

Via Investor's Business Daily

INVESTIGATION ALERT: Halper Sadeh LLP Investigates VMW, TPTX, CTT, CTEK

June 09, 2022

NEW YORK, NY / ACCESSWIRE / June 9, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...

From Halper Sadeh LLP

Via AccessWire

10 Biggest Price Target Changes For Monday ↗

June 06, 2022

Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.

Via Benzinga

June 05, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

69 Biggest Movers From Friday ↗

June 06, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...

Via Benzinga

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More ↗

June 05, 2022

Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.

Via Benzinga

The Acquisition of Turning Point Therapeutics By BMY- Bristol- Myers.

June 03, 2022

BMY - Bristol-Myers Squibb in a transaction that values Turning Point Therapeutics (NASDAQ:TPTX). Report at roughly $4.1 billion, Bristol-Myers Squibb

Via Best Stocks

Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher ↗

June 03, 2022

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 03, 2022

Via Benzinga

Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump ↗

June 03, 2022

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday.

Via Benzinga

40 Stocks Moving In Friday's Mid-Day Session ↗

June 03, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.

Via Benzinga

TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders

June 03, 2022

From Halper Sadeh LLP

Via Business Wire

CrowdStrike (CRWD) Stock Dips Despite Earnings Beat ↗

June 03, 2022

CrowdStrike (CRWD) stock is falling on Friday despite a positive Q1 fiscal 2023 earnings report from the cybersecurity company.

Via InvestorPlace

TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics ↗

June 03, 2022

Turning Point Therapeutics (TPTX) stock is rocketing higher on Friday following news of a deal with Bristol-Myers Squibb (BMY).

Via InvestorPlace

Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May ↗

June 03, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday.

Via Benzinga

Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead? ↗

June 03, 2022

Bristol Myers is moving deeper into the targeted oncology space.

Via Investor's Business Daily

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 03, 2022

Via Benzinga

Expert Ratings for Turning Point ↗

May 20, 2022

Over the past 3 months, 4 analysts have published their opinion on Turning Point (NASDAQ:TPTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022 ↗

May 20, 2022

Upgrades

Via Benzinga

Turning Point Therapeutics Gets FDA Breakthrough Therapy designation For Repotrectinib ↗

May 10, 2022

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate Repotrectinib in Patients With One...

Via Benzinga

Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

April 14, 2022

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...

Via FinancialNewsMedia

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.